Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer

被引:53
作者
Ameyaw, MM
Tayeb, M
Thornton, N
Folayan, G
Tariq, M
Mobarek, A
Evans, DAP
Ofori-Adjei, D
McLeod, HL
机构
[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[2] Univ Aberdeen, Inst Med Sci, Dept Med & Therapeut, Aberdeen, Scotland
[3] Riyadh Armed Forces Hosp, Riyadh, Saudi Arabia
[4] Univ Ghana, Sch Med, Ctr Trop Clin Pharmacol, Accra, Ghana
关键词
HER-2; codon; 655; single-nucleotide polymorphism; allele; ethnic variation;
D O I
10.1007/s100380200019
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
HER-2, a protooncogene located on chromosome 17q21, encodes a transmembrane glycoprotein (p185) with tyrosine kinase activity. Alterations of the HER-2 gene have been implicated in the carcinogenesis and prognosis of breast cancer and other solid tumors. It is also a cancer-therapeutic target for antibody-bused therapy against the HER-2 protein. A single-nucleotide polymorphism (SNP) at codon 655. resulting in a G-to-A transition (Ile655Val) in the transmembrane domain-coding region of this gene has been associated with an increased risk, of breast cancer. particularly among younger women. To understand the importance of this finding throughout the world. we evaluated this polymorphism in Ghanaian, Kenyan. Sudanese, Caucasian. African-American. Saudi. and Filipino subjects using a polymerase chain reaction-restriction fragment length polymorphism assay. The frequency of the Val allele. which is associated with increased breast cancer risk, was highly variable between populations (0%-24%). Continental African populations had a lower frequency of the Val allele than did Saudi. Chinese. Filipino. Caucasian, and African-American subjects, The data suggest that this SNP has variable frequency in different ethnic groups. The findings in this study correspond with the lower incidence and lower risk of breast cancer in African women compared With Caucasian and African-American women.
引用
收藏
页码:172 / 175
页数:4
相关论文
共 31 条
[1]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[2]   Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk [J].
Ameyaw, MM ;
Thornton, N ;
McLeod, HL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (23) :1947-1947
[3]   MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
CELL, 1986, 45 (05) :649-657
[4]   HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY [J].
CARTER, P ;
PRESTA, L ;
GORMAN, CM ;
RIDGWAY, JBB ;
HENNER, D ;
WONG, WLT ;
ROWLAND, AM ;
KOTTS, C ;
CARVER, ME ;
SHEPARD, HM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4285-4289
[5]  
CAVALLISFORZA II, 1996, HIST GEOGRAPHY HUMAN
[6]  
Chokunonga E, 2000, INT J CANCER, V85, P54, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt
[7]  
54::AID-IJC10&gt
[8]  
3.0.CO
[9]  
2-D
[10]   TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].
COUSSENS, L ;
YANGFENG, TL ;
LIAO, YC ;
CHEN, E ;
GRAY, A ;
MCGRATH, J ;
SEEBURG, PH ;
LIBERMANN, TA ;
SCHLESSINGER, J ;
FRANCKE, U ;
LEVINSON, A ;
ULLRICH, A .
SCIENCE, 1985, 230 (4730) :1132-1139